[Treatment strategy for acquired aplastic anemia]

Area of Science:

• Hematology
• Internal Medicine
• Clinical Guidelines

Background:

• Aplastic anemia (AA) is a rare but serious bone marrow failure disorder.
• Previous diagnostic and treatment guidelines in Japan required updates to reflect current clinical practice and research findings.

Purpose of the Study:

• To outline the recently revised guidelines for the diagnosis and treatment of aplastic anemia in Japan.
• To detail changes in disease staging, recommended therapies, and stem cell transplantation protocols.

Main Methods:

• Revision of staging criteria for aplastic anemia, specifically for stage 2.
• Modification of standard immunosuppressive therapy (IST) protocols.
• Evaluation of conditioning regimens for allogeneic stem cell transplantation (SCT).

Main Results:

• Stage 2 AA is now divided into stage 2a (no RBC transfusion) and stage 2b (<2 RBC units/month).
• Stage 2b AA is recommended for treatment similar to stage 3 or higher.
• The standard IST for transfusion-dependent AA is now ATG+CsA+eltrombopag.
• Early initiation of CsA is advised for stage 1 and 2b AA.
• Reduced-dose cyclophosphamide (CY) with fludarabine is increasingly preferred over high-dose CY for SCT conditioning to mitigate cardiotoxicity.
• HLA-haploidentical SCT with post-transplant CY is recognized for its favorable outcomes in alternative donor settings.

Conclusions:

• The revised guidelines provide a more nuanced approach to aplastic anemia diagnosis and treatment.
• Updated IST and SCT protocols aim to improve patient outcomes and reduce treatment-related toxicity.